According to a freshly-amended 13G filing with the Securities and Exchange Commission, James E. Flynn‘s Deerfield Management has sold around 2.56 million shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), lowering its stake in the company to 3.44 million shares which amass 7.94% of the company’s float. As per its 13F filing for the June 30 reporting period, Deerfield Management’s stake in Vanda Pharmaceuticals consisted of almost 6 million common shares.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is, as the name suggests, a biopharmaceutical company, one which produces therapeutics for treating central nervous system disorders. The company’s stock has gained a robust 75.73% year-to-date, with most of those gains coming in the last five months. In its financial report for the second quarter of 2016, Vanda Pharmaceuticals disclosed a net loss per share of $0.01 and revenue of $36.03 million, compared to a net loss per share of $0.13 and revenue of $27.58 million for the same period a year earlier. Recently, Piper Jaffray set a price target of $19 on Vanda Pharmaceuticals’ stock, with a ‘Buy’ rating.
The number of hedge funds in our database long Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stood at 21 at the end of June, down by one from the end of the previous quarter. Some of the bullish investors encompassed Jim Simons’ Renaissance Technologies, which held a position valued at $1.7 million, Emmanuel Ferreira’s Convector Capital, with a position worth $783,000, Principal Global Investors’ Columbus Circle Investors, Jonathan Lourie and Stuart Fiertz’ Cheyne Capital, and Ken Griffin’s Citadel Investment Group.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Deerfield Mgmt | 0 | 3,435,576 | 0 | 3,435,576 | 3,435,576 | 7.94% |
| Deerfield Management Company | 0 | 3,435,576 | 0 | 3,435,576 | 3,435,576 | 7.94% |
| Deerfield Partners | 0 | 1,283,849 | 0 | 1,283,849 | 1,283,849 | 2.97% |
| Deerfield Special Situations Fund | 0 | 517,737 | 0 | 517,737 | 517,737 | 1.20% |
Page 1 of 6 – SEC Filing
DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks
If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.
Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Computer Programs & Systems Inc (CPSI): Stadium Capital Management Reports...
BJ’s Restaurants Inc (BJRI): Luxor Capital Group Slightly Lowers Its...
Cormorant Asset Management Doesn’t Think Corbus Pharmaceuticals Holdings...
InfraREIT Inc. (HIFR): HG Vora Capital Management Raises Stake
Ptc Therapeutics Inc. (PTCT): Camber Capital Management Adds 500,000 Shares...
Oceanfirst Financial Corp (OCFC): EJF Capital Adds to Its Position
